GleamWall
中文EN

MRKR Marker Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1094038 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-30.7%
TTM net income YoY14.8%
TTM EPS YoY58.3%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-365.9%
Net margin-275.9%
FCF margin—
EBITDA margin—

Returns

ROE-77.0%
ROA-63.3%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets20.9%
Debt / equity0.00x
Current ratio4.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue——$751,691$1.10M$1.23M$861,184$349,104$2.25M
R&D expense$2.17M$1.48M$2.84M$2.14M$2.35M$4.18M$3.14M$5.09M
SG&A expense$1.06M$1.14M$1.23M$846,606$1.02M$945,163$1.37M$1.03M
Operating income-$3.23M-$2.62M-$4.07M-$1.88M-$3.37M-$5.12M-$4.96M-$3.86M
Net income-$1.84M-$1.83M-$3.18M-$1.70M-$2.00M-$4.02M-$4.45M-$3.84M
EPS (basic)-0.10-0.09-0.16—-0.12-0.29-0.40—
EPS (diluted)-0.10-0.09-0.16—-0.12-0.29-0.40—
Weighted avg. shares (diluted)19.31M19.31M19.31M—16.76M13.96M11.11M—
Balance sheet
Cash & equivalents$9.04M$11.33M$14.92M$16.07M$18.94M$11.81M$13.69M$19.19M
Current assets$12.50M$14.59M$17.43M$19.07M$21.73M$14.77M$16.99M$22.02M
Total assets$12.50M$14.59M$17.43M$19.07M$21.73M$14.77M$16.99M$22.02M
Current liabilities$2.00M$2.42M$3.64M$2.27M$3.35M$4.28M$2.50M$3.46M
Total liabilities$2.00M$2.42M$3.64M$2.27M$3.35M$4.28M$2.50M$3.46M
Shareholders' equity$10.50M$12.17M$13.80M$16.80M$18.39M$10.49M$14.49M$18.56M
Shares outstanding16.70M16.70M16.70M16.70M16.70M11.30M11.20M10.70M
Cash flow statement
Operating cash flow-$2.49M-$3.72M-$1.40M-$1.90M-$2.74M-$1.88M-$5.50M-$4.70M
Financing cash flow———$0$9.86M$100$505$14.90M
Stock-based compensation$181,887$195,735$178,422$111,131$33,279$13,986$379,144$50,544

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.